Old Web
English
Sign In
Acemap
>
authorDetail
>
Xiaojun Huang
Xiaojun Huang
Peking Union Medical College
Cancer research
Medicine
in patient
Myeloid leukemia
third generation
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I -Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP)
2021
Blood
Jiang Qian
Dayu Shi
Zongru Li
Yue Hou
Yu Hu
Weiming Li
Xiaoli Liu
Na Xu
Yongping Song
Gongli Zhang
Li Meng
Zhenya Hong
Bingcheng Liu
Yan Li
Suning Chen
Mengxing Xue
Huanling Zhu
He Li
Xin Du
Jin Lou
Xiaohan Zhang
Yang Liang
Yu-Jun Dai
Zi Chen
Qian Niu
Lichuang Men
Dajun Yang
Yifan Zhai
Xiaojun Huang
Show All
Source
Cite
Save
Citations (0)
Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
2021
Blood
Jiang Qian
Dayu Shi
Zongru Li
Ya-Zhen Qin
Ting Zhao
Bingcheng Liu
Zi Chen
Qian Niu
Lichuang Men
Hengbang Wang
Dajun Yang
Yifan Zhai
Xiaojun Huang
Show All
Source
Cite
Save
Citations (0)
1